Pharma Focus Asia

TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123

Tuesday, January 28, 2020

TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China (including Mainland China, Hongkong, Taiwan and Macau).

The license agreement includes an upfront payment as well as milestone payments linked to finishing of various phases of clinical development and obtaining marketing approvals. Under the agreement TILT is eligible to receive upfront and milestone payments as well as significant royalties on future sales.

“We are very happy to give our flagship product TILT-123 into the expert hands of Biotheus. TILT-123 is a unique product developed for activation of T-cells, and currently under clinical development in Europe and soon in the US. Biotheus has an interesting portfolio of synergic compounds and valuable development expertise in immuno-oncology. We believe that this collaboration greatly supports the global development and commercialization of TILT-123 while making the product also available to Chinese cancer patients.” says Akseli Hemminki, MD, PhD, eMBA, Founder and CEO of TILT Biotherapeutics Ltd.

The patented TILT® technology is based on novel oncolytic viruses coding for cytokines. The constructs are unique in structure, sequence and function. TILT-123 is a human 5/3 chimeric adenovirus capable of replicating only in cells defective in retinoblastoma/p16 pathway, found in most human tumors. TILT-123 was further modified to insert expression sequences for two cytokines: human Tumor Necrosis Factor alpha (hTNFα) and human Interleukin 2 (hIL-2).

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024